Latest News for: pd-l1
Edit
PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand
PR Newswire 16 Jun 2026
The PD-L1 biomarker testing market is transitioning from conventional oncology diagnostics toward highly specialized biomarker-based testing platforms that support personalized immunotherapy decisions.
Edit
Replay: WIAA state softball recap, scores for championship games
Oshkosh Northwestern 14 Jun 2026
Edit
PD-1 and PD-L1 Inhibitors Market is Expected to Witness Robust Growth by 2034, Estimates DelveInsight
GetNews 10 Jun 2026
Interested to know which PD-1 and PD-L1 inhibitor therapies will capture the highest market share?. Download the report to understand the latest PD-1 and PD-L1 inhibitors market trends and forecasts - ... PD-1 and PD-L1 Inhibitors Market Overview.
Edit
Programmable DNA hydrogels for dual-mode PD-L1 suppression via polyvalent LYTAC mimics and transcriptional silencing
PNAS 08 Jun 2026
.
Edit
EU agricultural policy needs to make clear link between subsidies and emissions reductions
The Irish Times 08 Jun 2026
Before Ireland joined the then European Economic Community (EEC) in 1973, the Irish taxpayer provided substantial subsidies to Irish farmers, amounting to almost 3 per cent of national income ... UK government is still paying the cost of Brexit ... .
Edit
Can Canada handle a World Cup soccer boom? Fields, coaches and funding remain major concerns
Yahoo Daily News 08 Jun 2026
Edit
Hastings Tribune
03 Jun 2026
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis ...
Edit
EVSC braces for cost of school safety upgrades
Courier & Press - Evansville 03 Jun 2026
EVANSVILLE — Hold up a minute, said Evansville Vanderburgh School Corp. board member Chris Kiefer ... The study would include assessed valuation trends, tax base forecasts, circuit breaker modeling and projections of net property tax revenues ... $175,000.
Edit
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma (Agilent Technologies Inc)
Public Technologies 02 Jun 2026
Edit
The Essex Reporter
31 May 2026
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in ...
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan ...
Edit
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
PR Newswire 31 May 2026
Edit
ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01 (Bicara Therapeutics Inc)
Public Technologies 30 May 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
PR Newswire 28 May 2026
About OpamtistomigOpamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB.
Edit
Lactylation of PD-L1 by a lactyltransferase HAT1 dictates its protein stability and tumor immune evasion
PNAS 27 May 2026
... 1 (PD-L1) lactylation, linking tumor metabolism to immune evasion.
Edit
PD-1 and PD-L1 Inhibitors Competitive Landscape Witnesses Rapid Expansion as 180+ Biopharma Companies Advance Innovative ...
GetNews 27 May 2026
By binding PD-1, sasanlimab blocks its interaction with PD-L1 and PD-L2, thereby restoring T-cell activation and enhancing anti-tumor immune responses.
- 1
- 2
- Next page »